Department of Medicine, Residency Program, University of Washington, Seattle, WA.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Blood. 2022 Mar 17;139(11):1694-1706. doi: 10.1182/blood.2021014804.
In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after allogeneic hematopoietic cell transplantation (HCT) is an established independent indicator of poor outcome. To address how peri-HCT MRD dynamics could refine risk assessment across different conditioning intensities, we analyzed 810 adults transplanted in first or second remission after myeloablative conditioning (MAC; n = 515) or non-MAC (n = 295) who underwent multiparameter flow cytometry-based MRD testing before as well as 20 to 40 days after allografting. Patients without pre- and post-HCT MRD (MRDneg/MRDneg) had the lowest risks of relapse and highest relapse-free survival (RFS) and overall survival (OS). Relative to those patients, outcomes for MRDpos/MRDpos and MRDneg/MRDpos patients were poor regardless of conditioning intensity. Outcomes for MRDpos/MRDneg patients were intermediate. Among 161 patients with MRD before HCT, MRD was cleared more commonly with a MAC (85 of 104; 81.7%) than non-MAC (33 of 57; 57.9%) regimen (P = .002). Although non-MAC regimens were less likely to clear MRD, if they did, the impact on outcome was greater. Thus, there was a significant interaction between conditioning intensity and "MRD conversion" for relapse (P = .020), RFS (P = .002), and OS (P = .001). Similar findings were obtained in the subset of 590 patients receiving HLA-matched allografts. C-statistic values were higher (indicating higher predictive accuracy) for peri-HCT MRD dynamics compared with the isolated use of pre-HCT MRD status or post-HCT MRD status for prediction of relapse, RFS, and OS. Across conditioning intensities, peri-HCT MRD dynamics improve risk assessment over isolated pre- or post-HCT MRD assessments in patients with AML.
在急性髓系白血病 (AML) 中,异体造血细胞移植 (HCT) 前后的可测量残留疾病 (MRD) 是预后不良的独立指标。为了研究移植前 MRD 动力学如何改善不同强度预处理条件下的风险评估,我们分析了 810 例接受清髓性预处理 (MAC;n = 515) 或非清髓性预处理 (n = 295) 后处于缓解期的成人患者,这些患者在移植前及移植后 20 至 40 天接受了基于多参数流式细胞术的 MRD 检测。无移植前和移植后 MRD(MRDneg/MRDneg)的患者复发风险最低,无复发生存率 (RFS) 和总生存率 (OS) 最高。与这些患者相比,MRDpos/MRDpos 和 MRDneg/MRDpos 患者的结局较差,且与预处理强度无关。MRDpos/MRDneg 患者的结局则处于中间水平。在 161 例移植前有 MRD 的患者中,MAC 方案(104 例中有 85 例,81.7%)比非 MAC 方案(57 例中有 33 例,57.9%)更常清除 MRD(P =.002)。尽管非 MAC 方案清除 MRD 的可能性较小,但如果清除了,对结局的影响更大。因此,预处理强度与“MRD 转换”对复发(P =.020)、RFS(P =.002)和 OS(P =.001)的交互作用具有显著意义。在接受 HLA 匹配同种异体移植的 590 例患者亚组中也得到了类似的结果。与孤立使用移植前 MRD 状态或移植后 MRD 状态相比,移植前和移植后 MRD 动力学对预测复发、RFS 和 OS 的 C 统计值更高(提示预测准确性更高)。在不同的预处理强度下,移植前和移植后 MRD 动力学改善了 AML 患者的风险评估,优于孤立使用移植前或移植后 MRD 评估。